Opinion|Videos|November 8, 2024
Intracranial Efficacy of Next-Generation ALK-Targeted Therapies
Panelists discuss the efficacy of ALK inhibitors in treating brain metastases, referencing data from the REMARK study, the CROWN trial, ALTA-3, and ALTA-1L/brigatinib, among others.
Advertisement
- All: Please discuss the efficacy of ALK inhibitors in brain metastases.
- REMARK study (Xiong A, et al. 2024. WCLC. OA09.03)
- CROWN trial (Solomon BJ, et al. Lancet Respir Med. 2023)
- ALTA-3 (Yang JC, et al. J Thorac Oncol. 2023)
- ALTA-1L/brigatinib (Camidge DR, et al. J Clin Oncol. 2021)
- Others
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5































